NYSE:CNMD - New York Stock Exchange, Inc. - US2074101013 - Common Stock - Currency: USD
Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q4 CY2024, with sales up 5.8% year on year to $345.9 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 2.7% below analysts’ estimates. Its non-GAAP profit of $1.34 per share was 11.4% above analysts’ consensus estimates.
Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q4 CY2024, with sales up 5.8% year on year to $345.9 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 2.7% below analysts’ estimates. Its non-GAAP profit of $1.34 per share was 11.4% above analysts’ consensus estimates.
CNMD stock results show that Conmed beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Conmed (NYSE:CNMD) just reported results for the second quarter of 2024.Conmed ...
Ride the coattails of institutional investors with these three overlooked stocks smart money investors are piling into for triple-digit gains.